Company Description
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.
It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies.
The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin’s lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM.
In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington’s disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder.
The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names.
It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH.
The company was founded in 1901 and is based in Tel Aviv, Israel.
| Country | Israel |
| Founded | 1901 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 37,851 |
| CEO | Richard Francis |
Contact Details
Address: 124 Dvora HaNevi’a Street Tel Aviv, 6944020 Israel | |
| Phone | 972 3 914 8213 |
| Website | tevapharm.com |
Stock Details
| Ticker Symbol | TEVA |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000818686 |
| CUSIP Number | 881624209 |
| ISIN Number | US8816242098 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Richard D. Francis | President, Chief Executive Officer and Director |
| Eliyahu Sharon Kalif | Executive Vice President and Chief Financial Officer |
| Mark Sabag | Executive Vice President of International Markets Commercial |
| Richard Gordon Daniell | Executive Vice President of European Commercial |
| Matthew Shields | Executive Vice President of Global Operations |
| Amir Weiss | Senior Vice President and Chief Accounting Officer |
| Ran Meir | Head of Investor Relations |
| Kathleen Veit | Senior Vice President, Global Compliance and Ethics Officer |
| David R. Mcavoy J.D. | Executive Vice President and Chief Legal Officer |
| Placid Jover | Executive Vice President and CHRO |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 20, 2024 | 144 | Filing |
| Nov 12, 2024 | 8-K | Current Report |
| Nov 12, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 6, 2024 | 10-Q | Quarterly Report |
| Nov 6, 2024 | 8-K | Current Report |
| Aug 14, 2024 | 144/A | Filing |
| Aug 14, 2024 | 144/A | Filing |
| Aug 12, 2024 | 144 | Filing |
| Aug 12, 2024 | 144 | Filing |
| Aug 9, 2024 | 144 | Filing |